Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-propionylated prostate-specific antigen-keyhole limpet hemocyanin is a synthetic conjugate designed for immunological research, primarily in the context of prostate cancer. It consists of N-propionylated fragments of prostate-specific antigen (PSA) chemically linked to Keyhole Limpet Hemocyanin (KLH), a highly immunogenic carrier protein derived from the marine mollusk Megathura crenulata. The purpose of conjugating the modified PSA fragments to KLH is to enhance their immunogenicity, thereby eliciting a robust immune response, such as the generation of specific antibodies. This construct is investigated for potential applications in developing novel diagnostic assays for prostate cancer by targeting differentially glycosylated PSA structures, or as a vaccine candidate to induce an immune response against prostate cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-propionylated prostate-specific antigen-keyhole limpet hemocyanin.